Back to search

Article

Repositioning of a Novel GABA-B Receptor Agonist, AZD3355 (Lesogaberan), for the Treatment of Non-alcoholic Steatohepatitis

2021-04-12

Abstract excerpt

Non-alcoholic steatohepatitis (NASH) is a rising health challenge, with no approved drugs. We used a computational drug repositioning strategy to uncover a novel therapy for NASH, identifying a GABA-B receptor agonist, AZD3355 (lesogaberan) previously evaluated as a therapy for esophageal reflux. AZD3355’s potential efficacy in NASH was tested in human stellate cells, human precision cut liver slices (hPCLS), and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e6b5feba-1aca-5065-b2d3-f2ac3d170593
DOI
10.21203/rs.3.rs-386482/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repositioning of a Novel GABA-B Receptor Agonist, AZD3355 (Lesogaberan), for the Treatment of Non-alcoholic SteatohepatitisDOI 10.21203/rs.3.rs-386482/v1
An LSEC-focused computational drug repurposing platform for liver fibrosis: Identification of vorinostat and other LSEC-protective candidatesSemantic proximity
A Systems Biology and Generative Artificial Intelligence Framework for Rational Multi-Target Drug Design in Metabolic Dysfunction-Associated Steatotic Liver Disease: Proof-of-Concept Identification of HPM-001Semantic proximity
Integrating Network Pharmacology and Experimental Validation to Elucidate Huaier in Attenuating Liver Fibrosis via the AKT Signaling PathwaySemantic proximity
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH modelSemantic proximity
Network Pharmacology Integrated with Multi-Dataset Machine Learning Identifies Core Diagnostic Biomarkers and Elucidates the Molecular Mechanism of a Traditional Chinese Medicine Transdermal Formula Against Non-Alcoholic Fatty Liver DiseaseSemantic proximity
Discovery of therapeutic agents targeting <i>PKLR</i> for NAFLD using drug repositioningSemantic proximity
Aspartame Drives the Continuous Progression from MASLD to HCC: An Integrated AnalysisSemantic proximity
A panorama to mine “bioactive X” against progressive deterioration of liver disease: from NAFLD to HCCSemantic proximity
GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHSemantic proximity
Exploring the Mechanism of Dendrobine in Treating Non-Alcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental ValidationSemantic proximity
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver diseaseSemantic proximity
The development and characterization of bile acid-derived agonists of FXR towards NASH treatmentSemantic proximity
Select a neighboring publication to make it the new centre.